Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer (Q39215738)

10 September 2017

title

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer (English)

1 reference

10 September 2017

1 reference

11

M J van de Vijver

1 reference

10 September 2017

S Rodenhuis

1

1 reference

10 September 2017

M Bontenbal

2

1 reference

10 September 2017

Q G C M van Hoesel

3

1 reference

10 September 2017

W M Smit

4

1 reference

10 September 2017

M A Nooij

5

1 reference

10 September 2017

E E Voest

6

1 reference

10 September 2017

E van der Wall

7

1 reference

10 September 2017

P Hupperets

8

1 reference

10 September 2017

H van Tinteren

9

1 reference

10 September 2017

J L Peterse

10

1 reference

10 September 2017

E G E de Vries

12

1 reference

10 September 2017

Netherlands Working Party on Autologous Transplantation in Solid Tumours

13

1 reference

10 September 2017

publication date

30 January 2006

1 reference

10 September 2017

1 reference

10 September 2017

volume

17

1 reference

10 September 2017

issue

4

1 reference

10 September 2017

page(s)

588-596

1 reference

Revision of the American Joint Committee on Cancer staging system for breast cancer

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantion incorporating carboplatin, cyclophosphamide and thiotepa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Bone marrow autotransplantation for solid tumors--prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL001

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDL001

1 reference

10 September 2017

1 reference